{"analyses":[{"ciLowerLimit":"0.56","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.94","estimateComment":"The reported 1-year PFS rate 80% (Exact 95% CI: 56% - 94%) was the proportion of the patients remained progression free after 12 months.","groupDescription":"Single-arm feasibility study; Kaplan Meier analysis was applied to estimate one-year PFS distribution as well as to calculate proportion of patients remain progression free by month 12.","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Single point estiamte of 1-yr PFS","paramValue":"0.8"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Progression free survival was calculated from the date of diagnosis to the date of disease progression as detected by clinical examination or imaging.","groups":[{"description":"Avastin and daily radiation\n\nAvastin : Avastin will be administered intravenously (vein) at 10mg/kg every two weeks starting day 1 for a total of 3 doses.","id":"OG000","title":"Avastin"}],"paramType":"NUMBER","populationDescription":"20 patients received and completed treatment.","reportingStatus":"POSTED","timeFrame":"1-year","title":"Single Point Estimate of 1-year Progression-free Survival of Patients Treated With Concurrent Avastin and Daily Pelvic Radiation With no Other Concurrent Chemotherapy","type":"SECONDARY","unitOfMeasure":"participants"}